These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 32329651)
1. The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer. Roth JA; Carlson JJ; Xia F; Williamson T; Sullivan SD J Manag Care Spec Pharm; 2020 Aug; 26(8):981-986. PubMed ID: 32329651 [TBL] [Abstract][Full Text] [Related]
2. The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma. Suh K; Carlson JJ; Xia F; Williamson T; Sullivan SD J Manag Care Spec Pharm; 2022 Jun; 28(6):622-630. PubMed ID: 35362337 [No Abstract] [Full Text] [Related]
3. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs MG; Shaw AT; de Braud F; Rolfo C; Ahn MJ; Wolf J; Seto T; Cho BC; Patel MR; Chiu CH; John T; Goto K; Karapetis CS; Arkenau HT; Kim SW; Ohe Y; Li YC; Chae YK; Chung CH; Otterson GA; Murakami H; Lin CC; Tan DSW; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Doebele RC; Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015 [TBL] [Abstract][Full Text] [Related]
4. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586 [TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic Suh K; Carlson JJ; Xia F; Williamson T; Sullivan SD J Comp Eff Res; 2022 Oct; 11(14):1011-1019. PubMed ID: 35993247 [No Abstract] [Full Text] [Related]
6. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD; Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007 [TBL] [Abstract][Full Text] [Related]
7. Projecting long-term clinical outcomes with larotrectinib compared with immune checkpoint inhibitors in metastatic nonsmall cell lung cancer and differentiated thyroid cancer. Suh K; Kang A; Ko G; Williamson T; Liao N; Sullivan SD J Manag Care Spec Pharm; 2024 Jun; 30(6):581-587. PubMed ID: 38824630 [TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer. Carlson JJ; Italiano A; Brose MS; Federman N; Lassen U; Kummar S; Sullivan SD Am J Manag Care; 2022 Jan; 28(2 Suppl):S26-S32. PubMed ID: 35201681 [TBL] [Abstract][Full Text] [Related]
9. Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers. Garcia-Foncillas J; Bokemeyer C; Italiano A; Keating K; Paracha N; Fellous M; Marian M; Fillbrunn M; Gao W; Ayyagari R; Lassen U Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406565 [TBL] [Abstract][Full Text] [Related]
10. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Drilon A; Siena S; Ou SI; Patel M; Ahn MJ; Lee J; Bauer TM; Farago AF; Wheler JJ; Liu SV; Doebele R; Giannetta L; Cerea G; Marrapese G; Schirru M; Amatu A; Bencardino K; Palmeri L; Sartore-Bianchi A; Vanzulli A; Cresta S; Damian S; Duca M; Ardini E; Li G; Christiansen J; Kowalski K; Johnson AD; Patel R; Luo D; Chow-Maneval E; Hornby Z; Multani PS; Shaw AT; De Braud FG Cancer Discov; 2017 Apr; 7(4):400-409. PubMed ID: 28183697 [TBL] [Abstract][Full Text] [Related]
11. Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report. Kubota Y; Kawano M; Iwasaki T; Itonaga I; Tsumura H; Kaku N; Tanaka K Medicine (Baltimore); 2023 Dec; 102(49):e36232. PubMed ID: 38065851 [TBL] [Abstract][Full Text] [Related]
12. A RESPONSE TO "THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER". Ogale S; Zerbini CEH; Antoniou M; Freund R J Manag Care Spec Pharm; 2020 Dec; 26(12):1616-1617. PubMed ID: 33251994 [No Abstract] [Full Text] [Related]
13. Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC. Frampton JE Drugs; 2021 Apr; 81(6):697-708. PubMed ID: 33871816 [TBL] [Abstract][Full Text] [Related]
14. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy. Sartore-Bianchi A; Pizzutilo EG; Marrapese G; Tosi F; Cerea G; Siena S Expert Rev Anticancer Ther; 2020 May; 20(5):333-341. PubMed ID: 32223357 [No Abstract] [Full Text] [Related]
15. NTRK Fusion-positive Non-small-cell Lung Cancer: The Diagnosis and Targeted Therapy. Haratake N; Seto T Clin Lung Cancer; 2021 Jan; 22(1):1-5. PubMed ID: 33272813 [TBL] [Abstract][Full Text] [Related]
16. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer. Cho BC; Chiu CH; Massarelli E; Buchschacher GL; Goto K; Overbeck TR; Loong HHF; Chee CE; Garrido P; Dong X; Fan Y; Lu S; Schwemmers S; Bordogna W; Zeuner H; Osborne S; John T Lung Cancer; 2024 Feb; 188():107442. PubMed ID: 38171156 [TBL] [Abstract][Full Text] [Related]
17. Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data. Bokemeyer C; Paracha N; Lassen U; Italiano A; Sullivan SD; Marian M; Brega N; Garcia-Foncillas J JCO Precis Oncol; 2023 Jan; 7():e2200436. PubMed ID: 36689698 [TBL] [Abstract][Full Text] [Related]
18. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Hong DS; DuBois SG; Kummar S; Farago AF; Albert CM; Rohrberg KS; van Tilburg CM; Nagasubramanian R; Berlin JD; Federman N; Mascarenhas L; Geoerger B; Dowlati A; Pappo AS; Bielack S; Doz F; McDermott R; Patel JD; Schilder RJ; Tahara M; Pfister SM; Witt O; Ladanyi M; Rudzinski ER; Nanda S; Childs BH; Laetsch TW; Hyman DM; Drilon A Lancet Oncol; 2020 Apr; 21(4):531-540. PubMed ID: 32105622 [TBL] [Abstract][Full Text] [Related]
19. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer. Federman N; McDermott R Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968 [No Abstract] [Full Text] [Related]
20. Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancers. Hong DS; Drilon A; Wirth LJ Clin Adv Hematol Oncol; 2024; 22 Suppl 5(6):1-20. PubMed ID: 38953725 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]